These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33952461)

  • 1. Comparative Evaluation of Cellular Uptake of Free and Liposomal Doxorubicin Following Short Term Exposure.
    Zaleskis G; Garberyte S; Pavliukeviciene B; Krasko JA; Skapas M; Talaikis M; Darinskas A; Zibutyte L; Pasukoniene V
    Anticancer Res; 2021 May; 41(5):2363-2370. PubMed ID: 33952461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pharmacokinetics, tissue distribution and pharmacodynamics of liposomal and free doxorubicin in tumour-bearing mice following intratumoral injection.
    Ren S; Li C; Dai Y; Li N; Wang X; Tian F; Zhou S; Qiu Z; Lu Y; Zhao D; Chen X; Chen D
    J Pharm Pharmacol; 2014 Sep; 66(9):1231-9. PubMed ID: 24716458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics evaluation of a thermosensitive chitosan based hydrogel containing liposomal doxorubicin.
    Ren S; Dai Y; Li C; Qiu Z; Wang X; Tian F; Zhou S; Liu Q; Xing H; Lu Y; Chen X; Li N
    Eur J Pharm Sci; 2016 Sep; 92():137-45. PubMed ID: 27388491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J; Lee A; Lu Y; Lee RJ
    Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Cell Toxicity and Intracellular Uptake of Doxorubicin Exposed as a Solution or Liposomes: Implications for Treatment of Hepatocellular Carcinoma.
    Kullenberg F; Degerstedt O; Calitz C; Pavlović N; Balgoma D; Gråsjö J; Sjögren E; Hedeland M; Heindryckx F; Lennernäs H
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin.
    Mei L; Liu Y; Zhang Q; Gao H; Zhang Z; He Q
    J Control Release; 2014 Dec; 196():324-31. PubMed ID: 25450404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
    Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
    Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and characterization of liposomal doxorubicin hydrochloride with palm oil.
    Sabeti B; Noordin MI; Mohd S; Hashim R; Dahlan A; Javar HA
    Biomed Res Int; 2014; 2014():765426. PubMed ID: 24795894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
    Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
    Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo.
    Xiong XB; Huang Y; Lu WL; Zhang H; Zhang X; Zhang Q
    Pharm Res; 2005 Jun; 22(6):933-9. PubMed ID: 15948037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer.
    Füredi A; Szebényi K; Tóth S; Cserepes M; Hámori L; Nagy V; Karai E; Vajdovich P; Imre T; Szabó P; Szüts D; Tóvári J; Szakács G
    J Control Release; 2017 Sep; 261():287-296. PubMed ID: 28700899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular PK/PD Relationships of Free and Liposomal Doxorubicin: Quantitative Analyses and PK/PD Modeling.
    Soininen SK; Vellonen KS; Heikkinen AT; Auriola S; Ranta VP; Urtti A; Ruponen M
    Mol Pharm; 2016 Apr; 13(4):1358-65. PubMed ID: 26950248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
    Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effect of folate-targeted liposomal doxorubicin in KB tumor-bearing mice after intravenous administration.
    Riviere K; Huang Z; Jerger K; Macaraeg N; Szoka FC
    J Drug Target; 2011 Jan; 19(1):14-24. PubMed ID: 20353291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human placental cell and tissue uptake of doxorubicin and its liposomal formulations.
    Soininen SK; Repo JK; Karttunen V; Auriola S; Vähäkangas KH; Ruponen M
    Toxicol Lett; 2015 Dec; 239(2):108-14. PubMed ID: 26383631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-delivery of Doxorubicin and Ceramide in a Liposomal Formulation Enhances Cytotoxicity in Murine B16BL6 Melanoma Cell Lines.
    Chen L; Alrbyawi H; Poudel I; Arnold RD; Babu RJ
    AAPS PharmSciTech; 2019 Feb; 20(3):99. PubMed ID: 30719596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
    Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
    Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
    Arabi L; Badiee A; Mosaffa F; Jaafari MR
    J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-crosslinkable and intracellularly decrosslinkable biodegradable micellar nanoparticles: A robust, simple and multifunctional nanoplatform for high-efficiency targeted cancer chemotherapy.
    Zou Y; Fang Y; Meng H; Meng F; Deng C; Zhang J; Zhong Z
    J Control Release; 2016 Dec; 244(Pt B):326-335. PubMed ID: 27245309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.